Hologic Sets M & amp;A Sights on SuperSonic Imagine in $85M Deal
In an attempt to boost its imaging offerings for breast health, Hologic has made a binding offer to acquire SuperSonic Imagine for $85 million. Aix-En-Provence, France-based Sonic Imagine develops cart-based ultrasound products. Hologic also would make available funds to repay SuperSonic Imagineâs net debt in an amount not to exceed $43 million, equating to a maximum enterprise value of $85 million. SuperSonic Imagineâs main shareholders, who together hold 10,841,409 shares or about 46% of the outstanding share capital of the company, have agreed to sell their shares to Hologic at the price of â¬1.50 per share. If this acquisition is completed, Hologic will file a cash tender offer, which would not be subject to any condition precedent, for all the remaining shares of SuperSonic Imagine at the same price per share, which represents a premium of 42.9% over the closing price on June 19, 2019 and a premium of 45.7% over the volume-weighted average price over 60 trading days. âThis contemplated acquisition of SuperSonic Imagine by Hologic meets all our strategic objectives and would allow us to develop the Ultrasound activity within a group that shares our values, said MichÃ¨le Lesieur, CEO, of SuperSonic Imagine. This isnât the first time Hologic has made a move bolster its breast health offerings through an acquisition. In August of last year, MD+DI reported Hologic spending $85 m...
New J. Chem., 2020, Accepted Manuscript DOI: 10.1039/D0NJ00879F, PaperVipan Kumar, Bharvi Sharma, Liang Gu, Ruvesh Pascal Pillay, Nosipho Cele, Paul Awolade, Parvesh Singh, Mandeep Kaur A series of 1H-1,2,3 triazole grafted tetrahydro- β-carboline-chalcone/ferrocenylchalcone conjugates were synthesized and invitro evaluated against Estrogen Responsive (MCF-7) and Triple Negative (MDA-MB-231) breast cancer cells. Comparative analysis revealed the improvement of... The content of this RSS Feed (c) The Royal Society of Chemistry
Publication date: Available online 1 June 2020Source: European Journal of RadiologyAuthor(s): Jing Zhang, Yan Ma, Xueying Tan, Xintong Zhang, Ye Kang, Jianyi Li, Weidong Ren
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: 18F-fluorothymidine Sponsor: Chang Gung Memorial Hospital Completed
Publication date: Available online 1 June 2020Source: International Journal of PharmaceuticsAuthor(s): Venturina Stagni, Archontia Kaminari, Zili Sideratou, Elias Sakellis nvestigation, Spiros A. Vlahopoulos, Dimitris Tsiourvas
PROSTATE cancer has overtaken breast cancer to become the UK's most commonly diagnosed form of the disease. The development comes 10 years earlier than predicted after cases more than doubled in the past two decades, said Prostate Cancer UK.
Women under the age of 40 are more likely than older patients to have breast...Read more on AuntMinnie.comRelated Reading: More young women are developing breast cancer Breast cancer brings financial difficulty to young women Young women at risk of breast cancer need screening Women under 40 benefit from mammography, too DBT improves breast cancer screening in young women
(Tulane University) Researchers at Tulane University School of Medicine identified a gene that causes an aggressive form of breast cancer to rapidly grow. More importantly, they have also discovered a way to " turn it off " and inhibit cancer from occurring. The animal study results have been so compelling that the team is now working on FDA approval to begin clinical trials and has published details in the journal Scientific Reports.
Publication date: Available online 31 May 2020Source: Pharmacological ResearchAuthor(s): Yue Cao, Wangjia Cao, Yangmin Qiu, Yuxin Zhou, Qinglong Guo, Yuan Gao, Na Lu
Publication date: Available online 31 May 2020Source: Seminars in Cancer BiologyAuthor(s): Pilipow Karolina, Darwich Abbass, Agnese Losurdo